ReNeuron Group plc Investor presentations

TIDMRENE

ReNeuron Group plc

25 February 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

Investor presentations

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces it will be presenting at three investor events, providing an overview of the business and the progress being made by the Company as it focuses on its retinal disease programme and exosome and iPSC platforms.

Proactive One2One Investor Forum

ReNeuron will present at today's Proactive One2One Investor Forum, commencing at 6.00pm, with ReNeuron presenting at this time. The event brings together high net worth investors and private investors with an interest in growth stocks. Investors can register to attend the event here:

https://www.proactiveinvestors.co.uk/register/event_details/319

Shares Investor Evening Webinar

ReNeuron will present at the Shares Investor Evening Webinar, on Tuesday 2 March 2021. Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for investors to ask questions. The event will commence at 6.00pm and ReNeuron will present at 6.55pm. Investors can register to attend the event here: https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-020321

H.C. Wainwright Global Life Sciences Conference

The Company will present at the H.C. Wainwright Global Life Sciences Virtual Conference which is taking place on 9-10 March 2021. The conference will consist of panel discussions, company presentations, virtual events, and networking opportunities. The presentation will be available on demand during the conference. Investors can register for the conference here: https://hcwevents.com/globalconference/#toggle-id-1-closed

No new material information will be disclosed, and the presentations will be made available on the Company website shortly after the events here: http://www.reneuron.com/investors/presentations/

Contacts:

 
 ReNeuron                                                        www.reneuron.com/investors 
 Olav Hellebø, Chief Executive                                         Via Walbrook PR 
  Officer 
 Michael Hunt, Chief Financial Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                         [phone] 
 
 Allenby Capital Limited (Joint Broker) 
  James Reeve/George Payne (Corporate 
  Finance) 
  Tim Sohal (Sales & Corporate Broking)                                 [phone] 
 
 Walbrook PR (Media & Investor Relations)    [phone] or [e-mail] 
                                                          [phone] / +44 (0)7407 
 Paul McManus, Alice Woodings                                                       804 654 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUSABRARUUUAR

(END) Dow Jones Newswires

February 25, 2021 02:01 ET (07:01 GMT)